Related references
Note: Only part of the references are listed.Clinical and Immunological Insights on Severe, Adverse Neurotropic and Viscerotropic Disease following 17D Yellow Fever Vaccination
Maria Luiza Silva et al.
CLINICAL AND VACCINE IMMUNOLOGY (2010)
Immunogenicity and safety of IXIARO® (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age
A. Kaltenboeck et al.
VACCINE (2010)
Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses
Bruno Guy et al.
VACCINE (2010)
Direct random insertion of an influenza virus immunologic determinant into the NS1 glycoprotein of a vaccine flavivirus
Alexander A. Rumyantsev et al.
VIROLOGY (2010)
IC51 Japanese Encephalitis vaccine
Herwig Kollaritsch et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
Japanese Encephalitis in Travelers: Review of Cases and Seasonal Risk
Mads R. Buhl et al.
JOURNAL OF TRAVEL MEDICINE (2009)
Live Chimeric and Inactivated Japanese Encephalitis Virus Vaccines Differ in Their Cross-Protective Values against Murray Valley Encephalitis Virus
Mario Lobigs et al.
JOURNAL OF VIROLOGY (2009)
Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX®1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study
A. Kaltenboeck et al.
VACCINE (2009)
Experimental evidence that RNA recombination occurs in the Japanese encephalitis virus
Ching-Kai Chuang et al.
VIROLOGY (2009)
Past, Present, and Future of Japanese Encephalitis
Tobias E. Erlanger et al.
EMERGING INFECTIOUS DISEASES (2009)
Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates
Charles E. McGee et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Immune response during adverse events after 17D-derived yellow fever vaccination in Europe
Hi-Gung Bae et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes
Charles E. McGee et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes
Bali Pulendran et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
E protein domain III determinants of yellow fever virus 17D vaccine strain enhance binding to glycosaminoglycans, impede virus spread, and attenuate virulence
Eva Lee et al.
JOURNAL OF VIROLOGY (2008)
A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: Immunogenicity and anamnestic responses
Young Mo Sohn et al.
VACCINE (2008)
Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants
Salvacion Gatchalian et al.
VACCINE (2008)
Analysis of ChimeriVax Japanese Encephalitis Virus envelope for T-cell epitopes and comparison to circulating strain sequences
Anne S. De Groot et al.
VACCINE (2007)
Construction and biological characterization of artificial recombinants between a wild type flavivirus (Kunjin) and a live chimeric flavivirus vaccine (ChimeriVax-JE)
Konstantin V. Pugachev et al.
VACCINE (2007)
Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: A case-control study in Nepalese children 5 years after immunization
J. B. Tandan et al.
VACCINE (2007)
High stability of yellow fever 17D-204 vaccine:: A 12-year restrospective analysis of large-scale production
V. Barban et al.
VACCINE (2007)
A live, attenuated recombinant West Nile virus vaccine
TP Monath et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax™-DEN2) vaccine:: Phase I clinical trial for safety and immunogenicity
Farshad Guirakhoo et al.
HUMAN VACCINES (2006)
Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis
MB Appaiahgari et al.
MICROBES AND INFECTION (2006)
Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study
H Ohrr et al.
LANCET (2005)
New developments in flavivirus vaccines with special attention to yellow fever
KV Pugachev et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2005)
Cutaneous Delivery of a Live, Attenuated Chimeric Flavivirus Vaccine Against Japanese Encephalitis (ChimeriVax™-JE) in Non-Human Primates
Cheryl H. Dean et al.
HUMAN VACCINES (2005)
Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: Infant mice provide an accurate surrogate for the test in monkeys
TP Monath et al.
BIOLOGICALS (2005)
Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates
F Guirakhoo et al.
JOURNAL OF VIROLOGY (2004)
Immunogenicity and protective efficacy in mice of a formaldehyde-inactivated Indian strain of Japanese encephalitis virus grown in Vero cells
MB Appaiahgari et al.
VACCINE (2004)
Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax™-JE experimental vaccine
DWC Beasley et al.
VACCINE (2004)
A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys
F Guirakhoo et al.
JOURNAL OF VIROLOGY (2004)
Arguments for live flavivirus vaccines
A de Silva et al.
LANCET (2004)
Arguments for live flavivirus vaccines
J Hombach et al.
LANCET (2004)
Arguments for live flavivirus vaccines
BR Murphy et al.
LANCET (2004)
Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses
JS Mackenzie et al.
NATURE MEDICINE (2004)
Exchanging the yellow fever virus envelope proteins with modoc virus prM and E proteins results in a chimeric virus that is neuroinvasive in SCID mice
N Charlier et al.
JOURNAL OF VIROLOGY (2004)
Live flavivirus vaccines: reasons for caution
SJ Seligman et al.
LANCET (2004)
High fidelity of yellow fever virus RNA polymerase
KV Pugachev et al.
JOURNAL OF VIROLOGY (2004)
ChimeriVax-West Nile virus live-attenuated vaccine: Preclinical evaluation of safety, immunogenicity, and efficacy
J Arroyo et al.
JOURNAL OF VIROLOGY (2004)
Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): Phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen
TP Monath et al.
JOURNAL OF INFECTIOUS DISEASES (2003)
Comparison of protective efficacies of plasmid DNAs encoding Japanese encephalitis virus proteins that induce neutralizing antibody or cytotoxic T lymphocytes in mice
E Konishi et al.
VACCINE (2003)
Origin and evolution of Japanese encephalitis virus in southeast Asia
T Solomon et al.
JOURNAL OF VIROLOGY (2003)
A Japanese encephalitis virus peptide present on Johnson grass mosaic virus-like particles induces virus-neutralizing antibodies and protects mice against lethal challenge
M Saini et al.
JOURNAL OF VIROLOGY (2003)
Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: Genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates
F Guirakhoo et al.
VIROLOGY (2002)
Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: Relevance to development and safety testing of live, attenuated vaccines
TP Monath et al.
JOURNAL OF VIROLOGY (2002)
Clinical proof of principle for ChimeriVax™:: recombinant live, attenuated vaccines against flavivirus infections
TP Monath et al.
VACCINE (2002)
Plasmid DNA immunization against Japanese encephalitis virus: Immunogenicity of membrane-anchored and secretory envelope protein
R Kaur et al.
JOURNAL OF INFECTIOUS DISEASES (2002)
Protective mechanisms induced by a Japanese encephalitis virus DNA vaccine:: Requirement for antibody but not CD8+ cytotoxic T-cell responses
CH Pan et al.
JOURNAL OF VIROLOGY (2001)
Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study
MB Bista et al.
LANCET (2001)
Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases
M Martin et al.
LANCET (2001)
Molecular basis for attenuation of neurovirulence of a yellow fever virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE)
J Arroyo et al.
JOURNAL OF VIROLOGY (2001)
Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: Dose-response effectiveness and extended safety testing in rhesus monkeys
TP Monath et al.
JOURNAL OF VIROLOGY (2000)
Share Paper
